伊马替尼治疗慢性髓性白血病患者时瘦素的变化：靶向治疗的新效应
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.
作者信息
Mariani Stefania, Basciani Sabrina, Giona Fiorina, Lubrano Carla, Ulisse Salvatore, Gnessi Lucio
机构信息
Department of Experimental Medicine, Sapienza University of Rome, Italy.
Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Italy.
出版信息
Leuk Res Rep. 2013 Aug 8;2(2):58-60. doi: 10.1016/j.lrr.2013.07.001. eCollection 2013.
Abstract
We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.
摘要
我们在长期随访期间评估了9例接受伊马替尼治疗的年轻慢性髓性白血病（CML）患者的血清瘦素水平。还测量了体重指数（BMI）和脂肪量百分比（%FM）。9例患者中有8例的瘦素高于正常范围。1例患者的该激素低于参考值。所有受试者的BMI均正常，但3例患者的FM%略有增加。1例患者在停用伊马替尼后瘦素恢复到正常值。在改用间歇疗法的患者中也发现了瘦素趋于正常化的趋势。本研究表明，伊马替尼治疗可能导致瘦素改变。
相似文献
1
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.伊马替尼治疗慢性髓性白血病患者时瘦素的变化：靶向治疗的新效应
Leuk Res Rep. 2013 Aug 8;2(2):58-60. doi: 10.1016/j.lrr.2013.07.001. eCollection 2013.
2
Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.伊马替尼治疗前后MBCR-ABL p210阳性慢性髓性白血病患者中瘦素的状态：一种矛盾的情况。
Clin Lab. 2014;60(11):1845-52. doi: 10.7754/clin.lab.2014.140126.
3
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.甲磺酸伊马替尼治疗可降低慢性髓性白血病患者分子缓解时的中性粒细胞明胶酶相关脂质运载蛋白血清水平，并增加瘦素浓度。
Acta Haematol. 2012;127(1):1-6. doi: 10.1159/000330948. Epub 2011 Oct 4.
4
[Effect of anticancer treatment on leptin level, fat body mass (FM) and lean body mass (LBM)].[抗癌治疗对瘦素水平、脂肪体重（FM）和去脂体重（LBM）的影响]
Med Wieku Rozwoj. 2004 Apr-Jun;8(2 Pt 1):297-307.
5
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.接受600毫克伊马替尼治疗的加速期慢性髓性白血病患者细胞遗传学反应的长期持久性：GIMEMA慢性髓性白血病工作组7年随访经验
Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14.
6
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.
7
Aberrant expressions of leptin and adiponectin receptor isoforms in chronic myeloid leukemia patients.慢性髓性白血病患者中瘦素和脂联素受体亚型的异常表达。
Cytokine. 2012 Jan;57(1):61-7. doi: 10.1016/j.cyto.2011.10.004. Epub 2011 Nov 13.
8
Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase.慢性期慢性髓性白血病患者长期使用伊马替尼治疗后贫血情况的评估
Hematol Transfus Cell Ther. 2019 Oct-Dec;41(4):329-334. doi: 10.1016/j.htct.2019.03.006. Epub 2019 Jun 14.
9
Correlation of serum leptin concentrations with body composition and gender in Taiwanese hemodialysis patients without diabetes.台湾非糖尿病血液透析患者血清瘦素浓度与身体组成及性别的相关性
Ren Fail. 2003 Nov;25(6):953-66. doi: 10.1081/jdi-120026030.
10
Serum leptin monitoring in anorectic patients during refeeding therapy.厌食症患者再喂养治疗期间的血清瘦素监测
Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):278-82. doi: 10.1055/s-2003-41286.
引用本文的文献
1
Nutritional status and appetite-regulating hormones in early treatment of acute lymphoblastic leukemia among children and adolescents: a cohort study.儿童和青少年急性淋巴细胞白血病早期治疗中的营养状况和食欲调节激素：一项队列研究
Sao Paulo Med J. 2020 Mar;138(2):118-125. doi: 10.1590/1516-3180.2019.0307.r1.19112019. Epub 2020 Jun 1.
2
Leptin and its receptor in hematologic malignancies.血液系统恶性肿瘤中的瘦素及其受体
Int J Clin Exp Med. 2015 Nov 15;8(11):19840-9. eCollection 2015.
本文引用的文献
1
Anthropometric characteristics and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC).欧洲癌症与营养前瞻性调查（EPIC）中的人体测量特征与淋巴和髓系白血病风险。
Cancer Causes Control. 2013 Mar;24(3):427-38. doi: 10.1007/s10552-012-0128-2. Epub 2013 Jan 4.
2
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.青春期接受伊马替尼治疗的慢性髓性白血病儿童的骨代谢、生长速率及青春期发育
Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14.
3
Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell.双酚 A 诱导瘦素受体表达，为瘦素创造更多的结合位点，并在人卵巢癌细胞中激活 JAK/Stat、MAPK/ERK 和 PI3K/Akt 信号通路。
Toxicol Lett. 2012 May 5;210(3):332-7. doi: 10.1016/j.toxlet.2012.02.003. Epub 2012 Feb 10.
4
Aberrant expressions of leptin and adiponectin receptor isoforms in chronic myeloid leukemia patients.慢性髓性白血病患者中瘦素和脂联素受体亚型的异常表达。
Cytokine. 2012 Jan;57(1):61-7. doi: 10.1016/j.cyto.2011.10.004. Epub 2011 Nov 13.
5
Leptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathway.瘦素逆转 α-亚麻酸在 BCR-ABL 阳性白血病细胞中的促凋亡和抗增殖作用：涉及 PI3K 途径。
PLoS One. 2011;6(10):e25651. doi: 10.1371/journal.pone.0025651. Epub 2011 Oct 3.
6
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.甲磺酸伊马替尼治疗可降低慢性髓性白血病患者分子缓解时的中性粒细胞明胶酶相关脂质运载蛋白血清水平，并增加瘦素浓度。
Acta Haematol. 2012;127(1):1-6. doi: 10.1159/000330948. Epub 2011 Oct 4.
7
Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty.青春期前开始长期接受伊马替尼治疗的慢性髓性白血病青年患者出现严重少精子症。
Fertil Steril. 2011 Mar 1;95(3):1120.e15-7. doi: 10.1016/j.fertnstert.2010.08.060.
8
Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells.瘦素受体（OB-R）异构体的表达模式及重组瘦素对人造血恶性细胞中 OB-R、瘦素表达和细胞因子分泌的直接体外作用。
Cytokine. 2009 Dec;48(3):203-11. doi: 10.1016/j.cyto.2009.07.006. Epub 2009 Aug 7.
9
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.与酪氨酸激酶抑制剂相关的甲状腺功能减退：靶向治疗的一种新出现的毒性作用。
Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.
10
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.一名青春期接受伊马替尼治疗的男孩出现低骨密度及抑制素B/促卵泡生成素比值降低的情况。
Lancet. 2008 Jul 12;372(9633):111-112. doi: 10.1016/S0140-6736(08)61023-5.
Zotero 插件